Massard, C., & Krauß, J. (2019). First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer chemotherapy and pharmacology, 83(6), . https://doi.org/10.1007/s00280-019-03796-4
Chicago-Zitierstil (17. Ausg.)Massard, Christophe, und Jürgen Krauß. "First-in-human Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-CD27L Antibody-drug Conjugate AMG 172 in Patients with Relapsed/refractory Renal Cell Carcinoma." Cancer Chemotherapy and Pharmacology 83, no. 6 (2019). https://doi.org/10.1007/s00280-019-03796-4.
MLA-Zitierstil (9. Ausg.)Massard, Christophe, und Jürgen Krauß. "First-in-human Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-CD27L Antibody-drug Conjugate AMG 172 in Patients with Relapsed/refractory Renal Cell Carcinoma." Cancer Chemotherapy and Pharmacology, vol. 83, no. 6, 2019, https://doi.org/10.1007/s00280-019-03796-4.